N-[3,5-Bis(trifluoromethyl)benzyl]-2-methyl-4-phenyl-3-quinolinecarboxamide | 159818-67-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-[3,5-Bis(trifluoromethyl)benzyl]-2-methyl-4-phenyl-3-quinolinecarboxamide
• 英文别名: 2-Methyl-4-phenyl-quinoline-3-carboxylic acid 3,5-bis-trifluoromethyl-benzylamide；N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-methyl-4-phenylquinoline-3-carboxamide
• CAS: 159818-67-4
• 化学式: C₂₆H₁₈F₆N₂O
• 分子量: 488.432
• InChiKey: OMTBQCJYPXKIRM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.8
• 重原子数：
  35
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  N-[3,5-Bis(trifluoromethyl)benzyl]-2-methyl-4-phenyl-3-quinolinecarboxamide 、 碘甲烷 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.33h， 以48%的产率得到N-[3,5-Bis(trifluoromethyl)benzyl]-N,2-dimethyl-4-phenyl-3-quinolinecarboxamide
  参考文献：
  名称：

  A Non-Peptide NK₁ Receptor Agonist Showing Subpicomolar Affinity

  摘要：

  3-Quinolinecarboxamides have been synthesized and evaluated for their binding to the human NK1 receptor. Several secondary amide derivatives show NK1 receptor affinity in the picomolar range. The most active compound, hydroxymethylcarboxamide 3h showing an IC50 value in the subpicomolar range, behaved as an agonist of NK1 receptor in endothelial cell proliferation, inositol phosphate turnover, and NO-mediated cyclic GMP accumulation, thus proving it to be the first non-peptide NK, receptor agonist showing very high potency.

  DOI：

  10.1021/jm034219a
• 作为产物：
  描述：

  2-methyl-4-phenyl-3-quinolinecarboxylic acid 在 氯化亚砜 、 三乙胺 作用下， 以 氯仿 为溶剂， 反应 4.0h， 生成 N-[3,5-Bis(trifluoromethyl)benzyl]-2-methyl-4-phenyl-3-quinolinecarboxamide
  参考文献：
  名称：

  A Non-Peptide NK₁ Receptor Agonist Showing Subpicomolar Affinity

  摘要：

  3-Quinolinecarboxamides have been synthesized and evaluated for their binding to the human NK1 receptor. Several secondary amide derivatives show NK1 receptor affinity in the picomolar range. The most active compound, hydroxymethylcarboxamide 3h showing an IC50 value in the subpicomolar range, behaved as an agonist of NK1 receptor in endothelial cell proliferation, inositol phosphate turnover, and NO-mediated cyclic GMP accumulation, thus proving it to be the first non-peptide NK, receptor agonist showing very high potency.

  DOI：

  10.1021/jm034219a

文献信息

• Condensed heterocyclic compounds, their production and use
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：EP0585913A2

  公开（公告）日：1994-03-09

  Novel compound represented by the formula: wherein ring A may be substituted; ring B represents an optionally substituted benzene ring; either X or Y represents -NR¹- (R¹ represents a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group or an optionally substituted amino group), -O- or -S-, the other representing -CO-, -CS- or -C(R²)R2a- (R² and R2a independently represent a hydrogen atom or an optionally substituted hydrocarbon group), or either X or Y represents -N=, the other representing =CR³- (R³ represents a hydrogen atom, a halogen atom, an optionally substituted hydrocarbon group , an optionally substituted amino group, a substituted hydroxyl group or a mercapto group substituted by an optionally substituted hydrocarbon group); ........ represents a single or double bond; when ........ is a single bond, Z represents -CR⁴- (R⁴ represents a hydrogen atom, hydroxyl group or an optionally substituted hydrocarbon group) or a nitrogen atom, or (ii) when ........ is a double bond, Z represents a carbon atom; D represents a C₁₋₃ alkylene group which may be substituted by an oxo group or a thioxo group, or D and Y, taken together, may form a 5- to 7-membered ring which may be substituted by an oxo group or a thioxo group; E represents -NR⁵- (R⁵ represents a hydrogen atom or an optionally substituted hydrocarbon group), -O- or -S(O)n- (n is 0,1 or 2), or R⁵ and Y, taken together, may form a 5- to 7- membered ring which may be substituted by an oxo group or a thioxo group; G represents a bond or a C₁₋₃ alkylene group; Ar represents an optionally substituted aryl group or an optionally substituted heterocyclic group, provided that (1) when (i) -X-Y- represents - O-CO- or -CO-O-, (ii) D represents -CO- and (iii) E represents -NR⁵-, either (a) G represents a C₁₋₃ alkylene group and Ar represents a substituted aryl group or a substituted heterocyclic group, or (b) G represents a bond and R⁵ represents an optionally substituted hydrocarbon group, and (2) when -X-Y- represents -NH-CO-, D represents -CO-, or a salt thereof having an excellent activity of inhibiting ACAT, lowering chlesterol in blood and inhibiting tachykinin recepter, or a salt thereof, their production and use.

  由式表示的新型化合物： 其中环 A 可被取代 环 B 代表任选取代的苯环； X或Y代表-NR¹-（R¹代表氢原子、任选取代的烃基、任选取代的羟基或任选取代的氨基）、-O-或-S-，另一个代表-CO-、-CS-或-C(R²)R2a-（R²和R2a独立地代表氢原子或任选取代的烃基）、或 X 或 Y 代表-N=，另一个代表 =CR³-（R³ 代表氢原子、卤素原子、任选取代的烃基、任选取代的氨基、取代的羟基或被任选取代的烃基取代的巯基）； ........ 代表单键或双键； 当 ........ 为单键时，Z 代表-CR⁴-（R⁴ 代表氢原子、羟基或任选取代的烃基）或氮原子；或 (ii) 当 ........ 为双键时，Z 代表碳原子； D 代表可被氧代基团或硫代基团取代的 C₁₋₃亚烷基，或 D 和 Y 合在一起可形成可被氧代基团或硫代基团取代的 5-7 元环； E 代表-NR⁵-（R⁵ 代表氢原子或任选取代的烃基）、-O-或-S(O)n-（n 为 0、1 或 2），或 R⁵ 和 Y 合在一起可形成可被氧代基团或硫代基团取代的 5-7 分子环； G 代表键或 C₁₋₃ 亚烷基； Ar 代表任选取代的芳基或任选取代的杂环基，条件是 (1) 当(i)-X-Y-代表-O-CO-或-CO-O-，(ii)D 代表-CO-和(iii)E 代表-NR⁵-时， (a) G 代表 C₁₋₃亚烷基，Ar 代表取代的芳基或取代的杂环基、(2) 当-X-Y-代表-NH-CO-时，D代表-CO-，或其盐具有抑制 ACAT、降低血液中胆固醇和抑制速激肽受体的优异活性，或其盐的生产和使用。
• US5482967A
  申请人：——

  公开号：US5482967A

  公开（公告）日：1996-01-09
• A Non-Peptide NK₁ Receptor Agonist Showing Subpicomolar Affinity
  作者：Andrea Cappelli、Germano Giuliani、Gal.la Pericot Mohr、Andrea Gallelli、Maurizio Anzini、Salvatore Vomero、Aroldo Cupello、Simona Scarrone、Mario Matarrese、Rosa Maria Moresco、Ferruccio Fazio、Federica Finetti、Lucia Morbidelli、Marina Ziche

  DOI：10.1021/jm034219a

  日期：2004.3.1

  3-Quinolinecarboxamides have been synthesized and evaluated for their binding to the human NK1 receptor. Several secondary amide derivatives show NK1 receptor affinity in the picomolar range. The most active compound, hydroxymethylcarboxamide 3h showing an IC50 value in the subpicomolar range, behaved as an agonist of NK1 receptor in endothelial cell proliferation, inositol phosphate turnover, and NO-mediated cyclic GMP accumulation, thus proving it to be the first non-peptide NK, receptor agonist showing very high potency.